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ditorialecommendations  for  strengthening  NITAG  policies  in  developed
ountriesVaccination constitutes one of the most signiﬁcant public
ealth advancements protecting millions of people from infectious
iseases worldwide and contributing to the socio-economic devel-
pment of nations on a global scale. Preventative in nature, vaccines
ave been traditionally used with the aim of directly avoiding or
educing overall incidence, morbidity, and mortality in healthy
ndividuals, proving vaccination is a highly cost-effective public
ealth intervention [1]. Yet, time to effective populations’ access to
ew vaccines is heterogeneous and lengthy in developed countries,
ith an average of 6.4 years between European Marketing Autho-
ization and effective populations’ access to new vaccines [2]. The
elay in access is mainly driven by the time taken by National
mmunization Technical Advisory Groups (NITAG) to issue vaccina-
ion recommendations guiding the executive policy-decisions [2].
icciardi et al. reported the heterogeneity in NITAG terms of ref-
rence and analytical decision frameworks that may  contribute to
he disparity in access to vaccination and immunization programs
cross developed countries [3]:
 In a study of 13 countries, publicly available information
on NITAGs’ policies and processes was very limited in most
countries, but more documented in the UK, US and Germany.
 The decision analysis frameworks that are critical for transpar-
ent, structured, reproducible and reliable decision-making, were
available for a limited number of NITAGs with only two  countries
(Germany and the US) using a detailed and standardized method-
ology for reliable, robust, and reproducible assessments (the
Grades of Recommendation, Assessment, Development and Eval-
uation – GRADE) [4–7].
 The lack of transparency in NITAGs’ interaction with the general
public and healthcare professionals deserves improvement. Few
NITAGs published their meeting agendas and minutes and only
the US had open meetings.
Throughout Europe, the decision-making process to include vac-
ines in national immunization policies is evolving in order for
overnments to ﬁnd optimal ways to facilitate timely and equi-
able access for populations to innovative vaccines. Countries like
weden, the Netherlands [8], Italy or France [9] have initiated
ebates with the various stakeholders including the vaccine indus-
ry in charge of developing and producing effective vaccines, the
ITAGs, in charge of evidence-based decisions regarding the vac-
inations strategies and the public health authorities in charge of
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.035
264-410X/© 2014 Elsevier Ltd. All rights reserved.the effective implementation to discover new methods of improv-
ing the system. As an illustration of this, the French Public Health
Council recently highlighted the complexity and inequality of the
current organization of vaccination in France proposing concrete
suggestions for change involving all key stakeholders, especially
regarding the need for a public consultation on compulsory vacci-
nation and for a strong public communication on the importance of
vaccination in France [9]. Concurrently, the Italian Superior Health
Council started the preparation of a National Plan aiming to reduce
the huge variability of immunization services between and among
the regions.
To ensure public trust in vaccination programs recommended
by health authorities, there is a need to enhance the transparency
of NITAGs’ decision-making process and to support the develop-
ment of best practices among the NITAGs, in view of strengthening
the reliability of immunization policies and programs. To meet this
objective the following four steps seem unavoidable from a short
term perspective:
- All NITAGs should have well deﬁned terms of reference that are
consistent with the actual NITAG practice.
- The decision framework should be evidence based, transparent,
structured, reproducible, reliable, and should follow a standard-
ized process such as GRADE.
- Transparency of communication should be established with, at
the very least, an agenda, decisions and technical reports that are
available to the public. Ideally, meetings should be open to the
public.
- Economic considerations, such as cost-effectiveness analysis and
budget impact estimate should be part of the framework analysis
at NITAG level. However, pricing and reimbursement should be
dealt with through another body.
Experience in the US and Germany supports the applicability of
evidence based structured process for NITAG vaccine recommen-
dation. Moreover, in the US, availability of meetings to the public
did not hinder NITAG recommendations.
At this time of booming communication, the lack of trans-
parency and of NITAGs’ recommendations will give ammunition
to vaccine detractors that are gaining space every year. The imple-
mentation of the four recommended steps seems to be the only
way to reinforce credibility and legitimacy of vaccination, one of
the most effective public health interventions to date.
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